Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.64 - $5.34
Previous CloseN/A
Volume1.63M
Average Volume (3M)11.68M
Market Cap
$1.55B
Enterprise Value$2.75B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 26, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding604,501,040
10 Day Avg. Volume14,508,662
30 Day Avg. Volume11,682,794
Standard Deviation0.18
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)52.49
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.28
Enterprise Value/Ebitda-14.26
Forecast
1Y Price Target
$8.20Price Target Upside220.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Geron News
PremiumCompany Announcements
Geron to Showcase RYTELO Success at Healthcare Conference
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGERN reported preliminary 4Q24 Rytelo product revenue surpassing the Consensus estimate and demonstrating significant sequential growth.
Intellectual PropertyGERN continues to quietly make progress on building a robust IP estate for Rytelo, with issuance of a new method patent and inclusion of another method patent with expiry in 2039 in the FDA Orange Book.
Regulatory ApprovalThe EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Rytelo in patients with LR-MDS who are ESA.
Bears Say
Commercial OpportunityThe two biggest bear pushbacks on GERN are uncertainty on exclusivity duration and lack of conviction on the commercial opportunity.
Exclusivity ConcernsThe IP life of Rytelo continues to be a barrier for some prospective investors who argue that it is hard to build confidence in the exclusivity tail when protection into the mid-to-late 2030s is based on method of use only.
Market ExpectationsThe 4Q24 pre-announce is approximately in line with consensus and our estimate, but may come in slightly below more optimistic buy-side expectations.
---
Ownership Overview
0.16% Insiders
12.98% Mutual Funds
33.63% Other Institutional Investors
39.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $1.55B.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Feb 26, 2025 which is in 8 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Nov 07, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.044.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 604,501,040 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 0.468%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
---
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (220.31% Upside)
$8.20 (220.31% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 37.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.90%
12-Months-Change
Fundamentals
Return on Equity
-69.03%
Trailing 12-Months
Asset Growth
7.73%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start for RYTELO's market presence, successful financial strategies, and promising growth potential both in the U.S. and internationally. However, high operating expenses and the dependency on market success pose challenges.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$8.20
▲(220.31% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Exelixis
―
Karyopharm Therapeutics
―
Sorrento Therapeutics
―
Best Analysts Covering GERN
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+37.13%
reiterated a buy rating 6 months ago
Copying Kalpit Patel's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +37.13% per trade.
---